The landscape changed dramatically in 2025. With the FDA ending enforcement discretion for compounded tirzepatide, most patients now face a clear choice: FDA-approved Zepbound or Mounjaro. This article compares both options across FDA status, cost, effectiveness, safety, and insurance. All info is updated for 2026.
Key takeaways
- Brand tirzepatide (Mounjaro & Zepbound) is fully FDA-approved, while compounded versions are mostly illegal in 2026.
- Compounded tirzepatide can only be used in rare medical cases, such as documented allergies to inactive ingredients.
- Compounded products vary by pharmacy and may have inconsistent potency, contamination risk, or untested formulations.
- Clinical trials show brand tirzepatide can reduce body weight by ~20%, while compounded versions lack solid evidence.
- Common side effects for both forms include nausea, vomiting, diarrhea, and injection-site reactions; serious risks exist for both forms.
- Brand tirzepatide is covered by insurance for many patients, making it affordable even compared to former compounded pricing.
- Self-pay options through LillyDirect make Zepbound accessible without insurance, starting at $299/month.
- Fraudulent or mislabeled compounded products have been documented, making safety a major concern.
- Licensed healthcare providers at Heally’s platform can guide patients safely, help with insurance, and navigate any legal compounded exceptions.
Please, pay attention to important status update in 2026
The FDA ended enforcement discretion for compounding tirzepatide in March 2025. As of 2026, 503A compounding pharmacies cannot legally produce compounded tirzepatide except in narrow, medically documented cases. If a pharmacy is advertising compounded tirzepatide, verify its registration carefully – this may indicate illegal activity.
What is compounded tirzepatide?
Compounded tirzepatide was a pharmacy-prepared version of tirzepatide. It is the active ingredient in Mounjaro and Zepbound. It was available during a documented national drug shortage from 2022 to 2025.
During the shortage, licensed compounding pharmacies were permitted to prepare custom-dose formulations when FDA-approved products were unavailable. These came in multi-dose vials, custom strengths, and sometimes combinations with B-vitamins, at a significantly lower price than brand-name options.
What has changed in 2026?
On October 2, 2024, the FDA declared the tirzepatide shortage resolved. After a transition period, it ended enforcement discretion for 503A pharmacies on March 5, 2025, and 503B outsourcing facilities on March 19, 2025. Compounding tirzepatide simply to reduce cost or improve convenience is now considered an illegal copy of an approved drug under federal law.
Is it possible ti get compounded tirzepatide legally in 2026?
The only remaining legal pathway for compounded tirzepatide in 2026 is a narrow medical exception: a patient with a documented clinical need that brand-name formulations cannot meet – such as a verified allergy to an inactive ingredient. Routine cost savings or patient preference does not qualify.
What is regular (brand-name) tirzepatide?
Regular tirzepatide refers to Eli Lilly’s two FDA-approved medications:
- Mounjaro (tirzepatide) was FDA-approved in May 2022 for type 2 diabetes management in adults.
- Zepbound (tirzepatide) was FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with a weight-related condition. Also approved in 2024 for obstructive sleep apnea.
Both contain identical tirzepatide molecules but carry different FDA-approved indications – which matters significantly for insurance coverage. Both are injected once weekly using pre-filled pens, come in escalating dose strengths (2.5 mg to 15 mg), and are manufactured under FDA Current Good Manufacturing Practice (CGMP) standards.
How does tirzepatide work?
Tirzepatide is the world’s first dual GIP/GLP-1 receptor agonist. It activates two hormonal pathways simultaneously – GLP-1 and GIP – affecting appetite, gastric emptying, and glucose regulation. The landmark SURMOUNT-1 trial demonstrated average weight loss of approximately 20% of body weight over 72 weeks at the highest dose – greater than any single-receptor GLP-1 drug.
The difference between tirzepatide and compounded tirzepatide
| Factor | Regular tirzepatide (Mounjaro / Zepbound) | Compounded tirzepatide |
| FDA approval | Fully FDA-approved (Mounjaro 2022, Zepbound 2023) | Not FDA-approved; pharmacy-level regulation only |
| Legal status (2026) | Legal with valid prescription | Generally illegal; narrow medical exceptions only |
| Manufacturing | FDA CGMP – batch-tested for potency, sterility, contaminants | State pharmacy board oversight; quality varies by facility |
| Clinical evidence | Robust – SURMOUNT trials (~20% body weight loss) | No large-scale trials; anecdotal evidence only |
| Dose accuracy | Manufacturer-guaranteed, consistent | Variable; FDA has flagged incorrect concentrations |
| Safety profile | Well-characterized through clinical trials | Unknown risks; adverse events likely underreported |
| Cost with insurance | As low as $25/month (Lilly savings card + commercial ins.) | No insurance coverage in 2026 |
| Self-pay cost | $299–$449/month via LillyDirect (all doses) | Largely unavailable legally in 2026 |
| Insurance coverage | Yes – Mounjaro ~70–85% (T2D); Zepbound ~40–45% (weight) | None |
| Counterfeit risk | Low – sealed, traceable manufacturer supply chain | High – FDA has documented fraudulent products |
| Manufacturer support | Lilly savings programs, pharmacist support | None |
| Availability | Widely available nationwide | Compounding largely shut down as of 2025 |
The story of FDA approval & legal landscape for tirzepatide and compounded tirzepatide
The shortage history
Tirzepatide was placed on the FDA drug shortage list in December 2022 due to explosive demand after approval. Federal law (Section 503A and 503B of the Food, Drug, and Cosmetic Act) allows compounding pharmacies to prepare copies of approved drugs on the shortage list – opening the door for the compounded tirzepatide market.
The shortage resolution
On October 2, 2024, the FDA declared the shortage resolved after confirming Eli Lilly’s manufacturing capacity could meet national demand. The FDA provided a grace period: 503A pharmacies had until February 18, 2025, and 503B outsourcing facilities until March 19, 2025.
Court challenges & 2026 status
A federal district court denied their preliminary injunction on March 5, 2025. As of early 2026:
- 503A pharmacies cannot legally compound tirzepatide except for patients with documented medical necessity not met by branded products.
- 503B outsourcing facilities face a contested legal landscape – some have received FDA warning letters; others continue operating in a gray zone with unreliable supply and high legal risk.
- Eli Lilly has pursued civil lawsuits against numerous compounding operations, resulting in court injunctions shutting down several facilities.
Cost comparison for tirzepatide and compounded tirzepatide
Cost was the primary reason patients sought compounded tirzepatide. With that option largely off the table legally, here is what brand-name tirzepatide actually costs in 2026:
| Option | Effective Cost | Notes | Insurance |
| Zepbound (with insurance) | $25/month | $1,086 list price; requires commercial coverage + savings card | ~40–45% commercial plans |
| Mounjaro (with insurance, T2D) | $25/month | $1,080 list price; requires commercial coverage + savings card | ~70–85% commercial plans |
| Zepbound self-pay (LillyDirect) | $299–$449/month | Starting dose $299; maintenance $449. No insurance needed. | Available at LillyDirect + Walmart |
| Medicare (2026 expansion) | ~$50/month* | *Projected copay. Currently covers OSA; weight mgmt expanding. | Savings cards not eligible |
| Compounded tirzepatide | N/A in 2026 | Largely illegal. Was $150–$300/month during shortage period. | No coverage |
No insurance? The LillyDirect self-pay vial program ($299–$449/month) makes brand-name Zepbound affordable without insurance – often competitive with what compounded tirzepatide cost during the shortage.
Effectiveness & clinical evidence comparation
Brand-name tirzepatide has robust trial data
FDA-approved tirzepatide’s efficacy is supported by the SURMOUNT clinical trial program:
- SURMOUNT-1: participants without diabetes achieved average weight loss of approximately 20% of body weight over 72 weeks at the 15 mg dose (vs. ~3% for placebo).
- SURMOUNT-2: adults with type 2 diabetes lost up to ~15% of body weight.
- SURMOUNT-3 and -4: demonstrated continued weight loss with sustained treatment, and significant regain when medication was stopped – supporting ongoing use.
Compounded tirzepatide has no clinical evidence base
No large-scale randomized controlled trials have been conducted on compounded tirzepatide formulations. Available evidence is anecdotal or from small case reports. Given the variability in compounding practices and dosing accuracy, efficacy cannot be assumed equivalent to SURMOUNT trial data.
The FDA has received adverse event reports specifically linked to compounded GLP-1 products involving incorrect dosing and concentration errors – a risk entirely absent from the SURMOUNT trial data.
Safety profile for regular and compounded tirzepatide
Known side effects for both forms
- Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, injection-site reactions. Most common during dose escalation; typically improve over time.
- Serious side effects: pancreatitis, gallbladder disease, acute kidney injury, hypoglycemia (especially with insulin), severe allergic reactions.
Thyroid warning: animal studies showed thyroid C-cell tumors; relevance to humans is unknown. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Additional risks specific to compounded versions
The FDA has documented fraudulent compounded tirzepatide products with false label information, including products bearing names of pharmacies that did not actually compound them.
- Incorrect concentration: compounded vials with wrong potency can cause overdose or ineffective treatment.
- Contamination: without mandatory FDA sterility testing, contamination risk is higher.
- Salt form uncertainty: some compounders used tirzepatide sodium or tirzepatide acetate – forms not tested for safety or efficacy in humans.
- Underreporting: 503A pharmacies are not required to submit adverse events to the FDA, so safety problems are likely underreported.
Quality & consistency for tirzepatide forms
Manufacturing quality is one of the starkest differences between brand-name and compounded tirzepatide:
- Eli Lilly’s manufacturing follows FDA CGMP standards – every batch is tested for potency, sterility, identity, and absence of contaminants before release. Dosing is precisely calibrated for each pen.
- Compounding pharmacies are regulated at a significantly lower standard. Quality depends heavily on the individual facility’s practices, equipment, and personnel.
- Compounded tirzepatide must use approved bulk API from compliant manufacturers. The FDA has taken action against importing APIs from non-compliant foreign sources.
Which option is right for you? Check the brief decision guide
Given the current legal landscape, the decision framework has simplified considerably:
- Do you have a valid medical need for tirzepatide? (BMI 30+, or BMI 27+ with a weight-related condition, or type 2 diabetes) – If yes, proceed. If no, speak with a provider.
- Do you have commercial insurance? Request prior authorization for Zepbound (weight) or Mounjaro (T2D). If denied, appeal – 65%+ success rate with documentation.
- No insurance or denied? Use the LillyDirect self-pay vial program. Zepbound vials: $299/month at the starting dose, up to $449/month at maintenance doses. Available at LillyDirect.com and Walmart pharmacies.
- Do you have a documented allergy to an inactive ingredient in Mounjaro/Zepbound? This is the primary remaining legal basis for a compounded formulation in 2026. Must be documented and prescribed through a legitimate registered pharmacy.
- Still facing cost barriers? Explore the Lilly Cares Foundation (income-based assistance) or speak with a Heally provider about all options available in your state.
How to get tirzepatide prescription with Heally
Heally connects patients across the U.S. with licensed healthcare providers who specialize in GLP-1 weight management. A Heally provider can:
- Conduct a full clinical evaluation to determine whether Zepbound or Mounjaro is appropriate for you
- Submit prior authorization requests and assist with insurance navigation
- Guide you through Lilly’s savings programs, LillyDirect, and financial assistance options
- Monitor your treatment, manage side effects, and adjust dosing as needed
- Coordinate with a registered compounding pharmacy in rare cases where a documented medical exception applies
- Provide ongoing support including lab monitoring, nutrition guidance, and lifestyle coaching
Heally currently provides telehealth services in 40+ U.S. states. Tirzepatide available from $299/month. Telehealth consultation available within 24–48 hours.
FAQ
Q: Can I legally get compounded tirzepatide?
A: Only if you have a documented medical need that cannot be met by Mounjaro or Zepbound (e.g., allergy to inactive ingredients). Routine cost or convenience doesn’t qualify.
Q: How does brand tirzepatide compare to compounded versions?
A: Brand tirzepatide has robust trial data, precise dosing, FDA oversight, insurance coverage, and manufacturer support. Compounded forms have no large-scale evidence and carry safety risks.
Q: Which tirzepatide is more effective?
A: FDA-approved Mounjaro & Zepbound are proven through SURMOUNT trials (~20% weight loss). Compounded versions lack reliable clinical evidence.
Q: Can I get tirzepatide without insurance?
A: Yes. LillyDirect self-pay program offers Zepbound vials starting at $299/month. Heally providers can assist with access and guidance.
Q: What should I watch out for with compounded tirzepatide?
A: Fraudulent products, incorrect dosing, contamination, untested salt forms, and underreported adverse events.
Q: How do I get a prescription safely?
A: Consult a licensed provider via Heally or your local physician. Heally’s provider can guide you through insurance, savings programs, and legally allowable compounded exceptions if necessary.
Sources & references
- U.S. FDA. GLP-1 Supply Stabilization & Compounding Policy Clarification (Oct. 2024)
- U.S. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (Updated 2025)
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1. N Engl J Med. 2022;387:205–216
- NCPA. FDA Ends Compounding Discretion for Tirzepatide (March 2025)
- Eli Lilly. Zepbound Savings, Coverage & LillyDirect (2026)
- Reuters. US Judge Sides with FDA’s Removal of Lilly’s Weight Loss Drug from Shortage List (May 2025)
- PMC/NCBI. Clinical and Legal Considerations in Pharmacy Compounding
- FDA MedWatch. Adverse Event Reporting System
Medical disclaimer
This article is for educational purposes only and does not constitute medical advice. Tirzepatide (Mounjaro, Zepbound) is a prescription medication. Individual results vary significantly. Consult a qualified healthcare provider before starting, changing, or stopping any treatment. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Common side effects include nausea, vomiting, diarrhea, constipation, and injection-site reactions. Serious risks include pancreatitis, gallbladder disease, and acute kidney injury. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Report adverse events to FDA MedWatch at fda.gov/medwatch or 1-800-FDA-1088.